Medicare protection of Novo Nordisk’s Wegovy might value as much as $145B yearly


Two packages of a fictitious Semaglutide drug used for weight loss (antidiabetic or anti-obesity medication) on a blue transparent background. Fictitious package design. Two dosing pens in front.

aprott/iStock by way of Getty Photographs

Novo Nordisk’s (NVO) weight reduction drug Wegovy (semaglutide), which may be prescribed to Medicare beneficiaries who’re each overweight and have heart problems, might value the system as much as $145B per yr.

If all beneficiaries who’re eligible for Wegovy

Leave a Reply

Your email address will not be published. Required fields are marked *